GAMMA Investing LLC Buys 8,394 Shares of LivaNova PLC (NASDAQ:LIVN)

GAMMA Investing LLC raised its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 2,299.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,759 shares of the company's stock after acquiring an additional 8,394 shares during the quarter. GAMMA Investing LLC's holdings in LivaNova were worth $344,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of LIVN. Russell Investments Group Ltd. boosted its position in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares during the period. Sterling Capital Management LLC lifted its stake in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after buying an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division lifted its stake in shares of LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after buying an additional 290 shares during the last quarter. Vestcor Inc bought a new stake in shares of LivaNova during the 4th quarter worth $204,000. Finally, Optimize Financial Inc acquired a new position in LivaNova in the 4th quarter valued at $208,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Performance

LivaNova stock traded up $0.46 on Tuesday, hitting $46.03. The company's stock had a trading volume of 429,794 shares, compared to its average volume of 642,150. LivaNova PLC has a one year low of $32.48 and a one year high of $57.35. The firm has a market cap of $2.51 billion, a P/E ratio of -11.25 and a beta of 0.90. The company has a quick ratio of 1.37, a current ratio of 1.58 and a debt-to-equity ratio of 0.53. The company has a fifty day moving average price of $41.83 and a 200-day moving average price of $43.54.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. The Goldman Sachs Group cut their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Robert W. Baird increased their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a report on Tuesday, May 20th. Finally, Mizuho lowered their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova presently has an average rating of "Buy" and a consensus price target of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.